Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460489 | 0.85 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL8950197 | 0.83 | KDM4E (0.47) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL215343 | 0.83 | TDP1 (0.46) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL13905046 | 0.82 | HPGD (0.50) | ALDH1A1SMN1; SMN2POLBLMNAPKM | |
| SCHEMBL18138425 | 0.81 | TDP1 (0.45) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL7815989 | 0.81 | NR1H4 (0.46) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL11748681 | 0.80 | KDM4E (0.44) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL5964869 | 0.80 | KDM4E (0.44) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL5964706 | 0.80 | TDP1 (0.44) | ALDH1A1SMN1; SMN2POLBHTTLMNA | |
| SCHEMBL1882600 | 0.80 | TDP1 (0.47) | ALDH1A1SMN1; SMN2POLBHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130229-A1 | Antitumor uses of compound | CELL THERAPEUTICS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20060258731-A1 | Antitumor compound and therapeutic uses thereof | CELL THERAPEUTICS, INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1534271-B1 | ANTITUMOR COMPOUND AND THERAPEUTIC USES THEREOF | CELL THERAPEUTICS EUROPE SRL (IT) | 2006-08-23 | — | — | EP | disclosed |
| US-20050209195-A1 | Indolinone derivatives | CELL THERAPEUTICS EUROPE S.R.I (IT) | 2005-09-22 | — | — | US | disclosed |
| CN-1668298-A | Antitumor compound and therapeutic uses thereof | NOVUSPHARMA SPA (IT) | 2005-09-14 | — | — | CN | disclosed |
| WO-2005068424-A1 | INDOLINONE DERIVATIVES AS RECEPTOR TYROSINE KINASE IHIBITORS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2005-07-28 | — | — | WO | disclosed |
| EP-1534271-A1 | ANTITUMOR COMPOUND AND THERAPEUTIC USES THEREOF | Cell Therapeutics Europe S.R.L. (IT) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004009083-A1 | ANTITUMOR COMPOUND AND THERAPEUTIC USES THEREOF | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258731-A1 | Antitumor compound and therapeutic uses thereof | FGFR3, KIT, RET | ALDH1A1 562/4885SMN1; SMN2 3775/4885POLB 4338/4885 |
| US-20090130229-A1 | Antitumor uses of compound | MET, FGFR2, FGFR3 | ALDH1A1 1326/4885SMN1; SMN2 1721/4885POLB 3674/4885 |
| US-20050209195-A1 | Indolinone derivatives | RET, MET, FGFR1 | ALDH1A1 510/4885SMN1; SMN2 4270/4885POLB 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.